TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily pill Juvmo, also known as tavapadon during clinical trials, on Sept. 25, 2026, to treat Parkinson’s symptoms. It is approved as a standalone treatment for early Parkinson’s and as an add-on in later stages; AbbVie expects U.S. availability in October. Trial results showed motor-symptom benefits, but the studies do not establish whether the drug reduces the risk of impulse-control problems.
The U.S. Food and Drug Administration approved AbbVie’s once-daily pill Juvmo on Sept. 25 to treat motor symptoms of Parkinson’s disease, authorizing it as a standalone option for people with early disease and as an add-on to existing treatment in later stages. The drug, called tavapadon during clinical trials, offers another medication choice for a condition that affects more than one million people in the United States, according to the report.
AbbVie expects Juvmo to be available in the United States in October 2026. The approval covers two uses: treatment on its own for early Parkinson’s symptoms and use alongside other Parkinson’s medications in later stages. The company’s development program tested both approaches.
Juvmo was evaluated in three randomized, placebo-controlled Phase 3 trials, each lasting 26 weeks and involving more than 1,300 participants in total. In two trials testing the drug alone, researchers found improvements in motor symptoms, with reported side effects that were generally mild to moderate, including nausea and headache. A third trial tested Juvmo as an add-on and found it helped extend “on time,” when medication is working, and reduce “off time,” when its effects have worn off.
Those findings describe results over the trials’ 26-week periods; they do not settle every question about longer-term effects. The report says the studies were not long enough to determine whether Juvmo reduces the risk of impulse-control problems, an adverse effect associated with some Parkinson’s medicines. The available information also does not provide a detailed comparison of Juvmo’s benefits and risks against specific alternative treatments.
A New Option for Motor Symptoms
Parkinson’s gradually damages neurons that produce dopamine, a chemical involved in movement. Existing medicines can help control symptoms such as tremors, stiffness and slowed movement, but some require dosing several times a day and can cause troublesome effects. Dyskinesia, or involuntary movements, and impulse-control disorders are among the concerns described in the report; side effects can lead some people to stop treatment.
Juvmo’s approval adds a once-daily option with two approved roles: treatment alone early in the disease and an add-on later. That gives clinicians another approach to discuss with patients whose symptoms or treatment experience call for a change. The approval does not mean the drug is free of side effects or appropriate for every patient. The trial results point to symptom improvements, while the extent of any advantage over existing medicines and its longer-term safety remain questions for clinical use and further evidence.
Neurologist Bryan Ho of Tufts Medical Center described the drug before approval as “not a huge game-changer, but definitely a nice additional tool to have,” according to Being Patient. He said he saw potential usefulness for older patients who may be more vulnerable to side effects from other therapies. That is a physician’s assessment, not a finding that Juvmo is safer for all older adults.
Parkinson's disease motor symptom medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Juvmo Differs From Older Drugs
Many existing medicines called dopamine agonists imitate dopamine by activating D2 and D3 receptor proteins. The report says activation of these pathways is linked to a range of medication side effects. Juvmo takes a different approach, activating dopamine pathways by targeting D1 and D5 receptors.
The distinction describes how the drug works; it does not by itself prove that patients will experience fewer adverse effects. The Phase 3 trials reported mild-to-moderate side effects such as nausea and headache, while questions about longer-term risks—including impulse-control problems—remain unresolved. The approval followed trials that tested Juvmo both by itself and as an addition to existing medication, matching its two authorized uses.
“It’s not a huge game-changer, but definitely a nice additional tool to have.”
— Dr. Bryan Ho, Tufts Medical Center neurologist, previously told Being Patient
As an affiliate, we earn on qualifying purchases.
Long-Term Risks Still Need Study
The reported clinical trials lasted 26 weeks, so they do not establish whether Juvmo changes the longer-term risk of impulse-control problems. The report also does not give detailed figures for the size of symptom improvements, the frequency of individual side effects, or head-to-head comparisons with other Parkinson’s medicines. Those details would help patients and clinicians weigh the new option against existing treatments.
AbbVie’s expected October availability is a company forecast, and the report does not specify a precise launch date, price, insurance coverage or patient access arrangements. It also does not provide the full FDA prescribing information, including all warnings, dosing instructions and restrictions. Patients should discuss treatment decisions with a qualified health professional rather than infer that once-daily dosing or a different receptor target guarantees fewer side effects.
As an affiliate, we earn on qualifying purchases.
U.S. Launch Expected in October
AbbVie expects Juvmo to reach the U.S. market in October 2026. The report does not give a specific date or details on pricing and coverage. Once the drug is available, clinicians and patients will be able to consider it under the FDA-approved uses: as a standalone treatment in early Parkinson’s or as an add-on in later stages.
Further use in routine care may provide more information about how the medication performs outside the 26-week trials, but the report identifies no additional study results or regulatory milestones. For now, the confirmed development is FDA approval; the launch timing is AbbVie’s expectation, and the drug’s longer-term effects remain uncertain.
Parkinson’s disease symptom management
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved AbbVie’s Juvmo, known as tavapadon during clinical trials, to treat Parkinson’s motor symptoms. It is authorized as a standalone treatment in early disease and as an add-on to existing medicines in later stages.
When is Juvmo expected to be available?
AbbVie expects the drug to be available in the United States in October 2026. The report does not give a specific launch date.
How does Juvmo work differently?
The report says Juvmo targets D1 and D5 dopamine receptors. Many existing dopamine agonists instead activate D2 and D3 receptors. This difference in mechanism does not, by itself, establish that Juvmo causes fewer side effects.
What did the trials find?
Three 26-week Phase 3 trials involving more than 1,300 participants tested Juvmo against placebo. Two trials found motor-symptom improvements when it was used alone; another found that add-on use helped extend medication “on time” and reduce “off time.” The report does not provide detailed effect sizes.
Does Juvmo prevent impulse-control problems?
The available trial period was not long enough to determine whether Juvmo reduces the risk of impulse-control problems. Its longer-term effects on that risk remain unclear.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
